Papapetropoulos Spyros insider trades
Papapetropoulos Spyros has filed 13 Form 4s with the SEC that we hold, for Lipocine Inc. (LPCN) (Director), Neuphoria Therapeutics Inc. (NEUP) (President and CEO, Director), VIGL (Chief Medical Officer) and ADMS (Director). Across all of them we count 2 purchases worth $23.8K and 1 sale worth $4.2K reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a purchase of 4,000 shares of VIGL worth $13.6K, dated 2022-05-03. The first filing on our record is dated 2021-11-24 and the latest 2025-09-02.
Lipocine Inc. (LPCN)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-11-22 | P, purchase reported on Form 4 | 21,739 | $10.2K | 2022-11-28 |
Neuphoria Therapeutics Inc. (NEUP)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
VIGL
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-05-03 | P, purchase reported on Form 4 | 4,000 | $13.6K | 2022-05-04 |
| 2022-11-18 | S, sale reported on Form 4 | 300 | $4.2K | 2022-11-22 |
ADMS
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1832694) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms